Core Viewpoint - The article discusses a class action lawsuit against Camping World Holdings, Inc. for allegedly making false statements and failing to disclose critical information regarding its financial performance and inventory management practices during a specified class period [1][3]. Group 1: Class Action Lawsuit Details - Investors who purchased Camping World securities between April 29, 2025, and February 24, 2026, can seek to be appointed as lead plaintiff by May 11, 2026 [1]. - The lawsuit, titled Siverd v. Camping World Holdings, Inc., accuses the company and certain executives of violating the Securities Exchange Act of 1934 [1][3]. Group 2: Allegations Against Camping World - The lawsuit alleges that Camping World overstated its inventory management capabilities and retail demand, which led to a need for strict inventory management that negatively impacted gross profit and margins [3]. - Specific financial results reported include a new vehicle revenue of $766.8 million for Q3 2025, a decrease of $58.1 million or 7.0%, and a gross margin of 12.7%, down 81 basis points due to an 8.6% decrease in average selling price [4]. - Following the release of Q4 2025 results, which included the announcement of pausing quarterly cash dividends, Camping World's share price fell more than 16% [5][6]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Camping World securities during the class period to seek lead plaintiff status, representing the interests of all class members [7]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is noted for its significant recoveries in securities class action lawsuits, having recovered over $916 million for investors in 2025 alone [8].

Core Viewpoint - The Trip.com Group Limited is facing a class action lawsuit due to allegations of misleading statements and failure to disclose regulatory risks associated with its monopolistic business practices during the specified class period from April 30, 2024, to January 13, 2026 [1][4][5]. Company Overview - Trip.com operates as a travel service provider, offering services such as accommodation reservations, transportation ticketing, packaged tours, in-destination services, and corporate travel management [3]. Allegations - The lawsuit claims that Trip.com and its executives made false or misleading statements and did not adequately disclose the regulatory risks stemming from their monopolistic activities [4][5]. - A significant event occurred on January 14, 2026, when Bloomberg reported that China was investigating Trip.com for alleged antitrust conduct, which led to a 19% drop in the price of Trip.com American Depositary Shares over two trading sessions [5]. Legal Process - Investors who purchased Trip.com securities during the class period have until May 11, 2026, to apply as lead plaintiffs in the class action lawsuit [1][6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7].

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. regarding allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves Vistagen and certain officers and/or directors accused of engaging in securities fraud or other unlawful business practices [2]. - Investors who purchased Vistagen securities during the Class Period have until March 16, 2026, to request to be appointed as Lead Plaintiff [2]. Group 2: Company Performance - On December 17, 2025, Vistagen announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for treating social anxiety disorder did not show a statistically significant improvement on the primary endpoint [4]. - Following this announcement, Vistagen's stock price dropped by $3.499 per share, equating to an 80.25% decline, closing at $0.861 per share on the same day [5].

Core Viewpoint - A class action lawsuit has been filed against Nektar Therapeutics and certain officers for alleged violations of federal securities laws during the Class Period from February 26, 2025, to December 15, 2025, seeking damages for affected investors [1]. Company Overview - Nektar Therapeutics is a biopharmaceutical company focused on developing therapies that modulate the immune system for treating autoimmune disorders [4]. - The company's lead product candidate is rezpegaldesleukin (REZPEG or NKTR-358), aimed at treating conditions such as alopecia areata [4]. Clinical Trial Information - In March 2024, Nektar initiated the Phase 2b REZOLVE-AA trial to evaluate rezpegaldesleukin in 94 patients with severe-to-very severe alopecia areata [5]. - The trial's enrollment criteria included specific diagnostic and treatment history requirements to ensure patient eligibility [5]. - By February 2025, Nektar announced the completion of target enrollment for the REZOLVE-AA trial, asserting compliance with applicable protocols [6]. Allegations and Misconduct - The Complaint alleges that during the Class Period, Nektar's executives made materially false and misleading statements regarding the company's operations and compliance, particularly concerning the REZOLVE-AA trial [7]. - Specific allegations include failure to disclose that enrollment did not adhere to protocol standards, which could negatively impact trial results and misrepresent the trial's integrity [7]. Disclosure of Trial Results - On December 16, 2025, Nektar released topline results from the REZOLVE-AA trial, indicating that the trial did not achieve statistical significance due to the inclusion of ineligible patients [8]. - Following this announcement, Nektar's stock price dropped by $4.14 per share, or 7.77%, closing at $49.16 per share [9].

Core Viewpoint - The Gartner class action lawsuit alleges that Gartner, Inc. and its executives made misleading statements regarding the company's contract value growth and consulting segment revenue, leading to significant stock price declines following disappointing earnings announcements [1][3][4][5]. Group 1: Lawsuit Details - The lawsuit, titled Schmidt v. Gartner, Inc., seeks to represent purchasers of Gartner common stock and claims violations of the Securities Exchange Act of 1934 [1]. - Allegations include that Gartner executives created a false impression of reliable information regarding contract value growth and minimized risks from macroeconomic factors [3]. - The lawsuit highlights that Gartner's non-federal contract value growth fell below projections, contradicting earlier statements about improving conditions for tariff-impacted companies [3]. Group 2: Financial Impact - On August 5, 2025, Gartner reported a decline in overall contract value growth from 7% to 5% and a drop in ex-federal contract value growth from 8% to 6%, resulting in a stock price drop of over 27% [4]. - On February 3, 2026, Gartner announced a further decline in contract value growth by 2%, including significant underperformance in its consulting segment, leading to a nearly 21% drop in stock price [5]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Gartner common stock during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [7].

Core Viewpoint - The Enphase Energy class action lawsuit alleges that the company and its executives made misleading statements regarding their financial and operational capabilities, leading to significant stock price declines following the disclosure of negative financial results [3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Tripathi v. Enphase Energy, Inc., and it involves purchasers of Enphase Energy securities from April 22, 2025, to October 28, 2025 [1]. - Investors have until April 20, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Enphase Energy overstated its ability to manage channel inventory and mitigate the effects of the termination of the Residential Clean Energy Credit [3]. Group 2: Financial Impact - On October 28, 2025, Enphase Energy reported that elevated channel inventory would lead to lower battery storage shipments in Q4 2025 and that the expiration of the 25D Credit would negatively impact revenues in Q1 2026 [4]. - Following this announcement, Enphase Energy's stock price fell by more than 15% [4]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Enphase Energy securities during the class period to seek lead plaintiff status [5]. - The lead plaintiff represents the interests of all class members and can choose a law firm to litigate the case [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Nektar Therapeutics (NKTR) on behalf of investors who acquired its securities between February 26, 2025, and December 15, 2025, due to alleged misleading statements and failure to disclose material adverse facts about the company's business and operations [1][3]. Summary by Sections Company Overview - Nektar Therapeutics is a biopharmaceutical company involved in developing treatments, including a drug for alopecia areata named rezpegaldesleukin [2]. Lawsuit Details - The lawsuit claims that during the class period, Nektar made materially false and misleading statements regarding the integrity and results of the Phase 2b REZOLVE-AA trial for rezpegaldesleukin [3]. - Specifically, it is alleged that the company failed to disclose that enrollment in the trial did not adhere to applicable protocols, which likely impacted the trial's results negatively [3]. Stock Impact - Following the announcement of the trial results on December 16, 2025, Nektar's stock price dropped by $4.14, or 7.8%, closing at $49.16 per share, resulting in financial harm to investors [2][3]. Investor Actions - Investors who purchased Nektar securities during the class period have until May 5, 2026, to file a lead plaintiff motion in the class action lawsuit [1][4].

Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages monday.com Ltd. (MNDY) Shareholders To Inquire About Securities Fraud Class Action Mar 17, 2026 2:19 PM Eastern Daylight Time Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages monday.com Ltd. (MNDY) Shareholders To Inquire About Securities Fraud Class Action What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially fa ...

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating DNOW Inc. for potential violations of federal securities laws, focusing on the company's financial results released on February 20, 2026 [1] Group 1 - DNOW Inc. is under scrutiny for possible legal issues related to its financial disclosures [1] - The investigation is initiated on behalf of investors who may have incurred losses from their investments in DNOW [1] - The specific financial results being examined are from the fourth quarter and full year of 2025 [1]

Core Viewpoint - Halper Sadeh LLC is investigating whether certain officers and directors of LivePerson, Inc. breached their fiduciary duties to shareholders [2]. Group 1: Investigation Details - The investigation focuses on potential breaches of fiduciary duties by LivePerson's officers and directors [2]. - Shareholders of LivePerson may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [3]. Group 2: Legal Representation - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4].